DK0864649T3 - Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat - Google Patents

Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat

Info

Publication number
DK0864649T3
DK0864649T3 DK98202021T DK98202021T DK0864649T3 DK 0864649 T3 DK0864649 T3 DK 0864649T3 DK 98202021 T DK98202021 T DK 98202021T DK 98202021 T DK98202021 T DK 98202021T DK 0864649 T3 DK0864649 T3 DK 0864649T3
Authority
DK
Denmark
Prior art keywords
hepatitis
surface antigen
hep
virus
vaccine composition
Prior art date
Application number
DK98202021T
Other languages
Danish (da)
English (en)
Inventor
Gonzalez Verena L Muzio
Galvez Marcelo Nazabal
Griego Marta De Jesu Gonzalez
Suarez Jose San Reafae Garcia
Zorrilla Filiberto Rosend Ayon
Maya Yair Quinones
Arias Eduardo Penton
Escobar Giuvel Fontirrochi
Iznaga Alejandro Beldarrain
Gonzalez Guillermo Juli Padron
Pena Arnaldo Garcia
Cruz Carlos Enrique Ruiz
Lopez Gladys Mabel Izquierdo
Martinez Luis Saturnin Herrera
Cano Carlos Antonio Duarte
Suarez Lilia Luisa Perez
La Riva Gustavo De
Avila Ramon Alexis Santiago
Meireles Rolando Paez
Fierro Alberto Agraz
Betancourt Raul Enrique Diaz
Albajes Victoria Ramirez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Application granted granted Critical
Publication of DK0864649T3 publication Critical patent/DK0864649T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK98202021T 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat DK0864649T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU90155A CU22290A1 (es) 1990-10-08 1990-10-08 Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
EP91202615A EP0480525B1 (de) 1990-10-08 1991-10-07 Verfahren zur Gewinnung von rekombinantem Hepatitis B Virus (HEP B) Oberflächeantigen

Publications (1)

Publication Number Publication Date
DK0864649T3 true DK0864649T3 (da) 2006-08-28

Family

ID=5459466

Family Applications (2)

Application Number Title Priority Date Filing Date
DK98202021T DK0864649T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat
DK91202615T DK0480525T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK91202615T DK0480525T3 (da) 1990-10-08 1991-10-07 Fremgangsmåde til opnåelse af rekombinant hepatitis B virus (HEP B) overfladeantigen med større immunogen kapacitet og anve

Country Status (9)

Country Link
EP (2) EP0480525B1 (de)
JP (2) JP3189212B2 (de)
AT (2) ATE324451T1 (de)
AU (1) AU649482B2 (de)
CU (1) CU22290A1 (de)
DE (2) DE69130724T2 (de)
DK (2) DK0864649T3 (de)
ES (2) ES2129025T3 (de)
GR (1) GR3029582T3 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0686696A1 (de) * 1994-06-09 1995-12-13 Centro De Ingenieria Genetica Y Biotecnologia Rekombinantes einkettiges Fv Antikörperfragment und dessen Verwendung zur Immunreinigung des rekombinanten Hepatitis B Virus Oberflächenantigens
KR960023066A (ko) * 1994-12-10 1996-07-18 성재갑 전에스 (s) 2 펩티드 함유 비 (b) 형 간염 표면항원의 정제 방법
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US6436402B1 (en) 1999-10-15 2002-08-20 Merck & Co., Inc. Process for making human papillomavirus virus-like particles with improved properties
EP1403274A1 (de) * 2002-09-30 2004-03-31 Meristem Therapeutics Verfahren zur Reinigung von rekombinanten Proteinen aus komplexen Medien sowie die auf diese Weise erhaltenen gereinigten Proteine
CU23405A1 (es) * 2003-10-20 2009-08-04 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas para uso terapéutico
JP4936272B2 (ja) * 2006-02-13 2012-05-23 独立行政法人科学技術振興機構 バイオナノカプセルの効率的な精製法
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN109219449B (zh) 2016-03-31 2022-08-30 遗传工程与生物技术中心 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物
KR102630293B1 (ko) * 2021-06-21 2024-01-29 선지호 박스 포장 테이프 절단용 칼날유닛과 이를 이용한 박스 포장 테이프 절단장치.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59101426A (ja) * 1982-11-29 1984-06-12 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
US5004688A (en) * 1988-04-15 1991-04-02 Phillips Petroleum Company Purification of hepatitis proteins
IL89991A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of hepatitis b pres2 protein in methylotrophic yeasts
KR900008591B1 (ko) * 1988-05-13 1990-11-26 동아제약 주식회사 항이디오형 항체를 용출제로 사용하는 면역친화성 크로마토그라프법에 의한 생리활성물질의 정제방법

Also Published As

Publication number Publication date
ES2264183T3 (es) 2006-12-16
AU649482B2 (en) 1994-05-26
AU8557491A (en) 1992-04-30
CU22290A1 (es) 1995-01-31
JP3242640B2 (ja) 2001-12-25
EP0480525B1 (de) 1999-01-07
EP0864649A3 (de) 1998-11-11
DE69133525T2 (de) 2006-11-23
EP0864649A2 (de) 1998-09-16
JPH0576370A (ja) 1993-03-30
EP0480525A3 (en) 1992-09-30
DE69130724D1 (de) 1999-02-18
ES2129025T3 (es) 1999-06-01
ATE324451T1 (de) 2006-05-15
JP2001231582A (ja) 2001-08-28
GR3029582T3 (en) 1999-06-30
EP0864649B1 (de) 2006-04-26
JP3189212B2 (ja) 2001-07-16
DE69133525T8 (de) 2007-03-08
EP0480525A2 (de) 1992-04-15
DE69133525D1 (de) 2006-06-01
DE69130724T2 (de) 1999-06-17
DK0480525T3 (da) 1999-08-30
ATE175445T1 (de) 1999-01-15

Similar Documents

Publication Publication Date Title
DK0864649T3 (da) Fremgangsmåde til opnåelse af rekombinant overfladeantigen af hepatitis B-virus (HEP B) med större immunogenevne og anvendelse deraf i et vaccinepræparat
DE69433971D1 (de) Von menschlichen T-Zellen immunodominante Epitopen des Virus der C-Hepatitis
DE3280284D1 (de) Herstellung von oberflaechen-hepatitis-b-antigen in hefe.
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
EP0484787A3 (en) Hcv-specific peptides, process for obtaining them and their use
PL279426A1 (en) Method of intensifying generation of antigenic hbv particles containing essentially s and pre s2 proteins
DK345685A (da) Hepatitis b vaccine
DK57284A (da) Fremgangsmaade til inaktivering af et lipidvirus
DK0425082T3 (da) Vacciner
EP0198299A3 (de) Verfahren zur Herstellung von Hepatitis-B-Oberflächenantigen enthaltenden Partikeln in neuer Form, die hoch immunogen sind
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
DK0412766T3 (da) Peptidfragmenter af HIV
DK1115420T3 (da) Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
DE60229126D1 (de) Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
DK645687D0 (da) Fremgangsmaade til fremstilling af en vaccine mod hepatitis b og den opnaaede vaccine
DE69104012T2 (de) Rekombiniebares Hepatitis-Delta-Antigen, Verfahren zu seiner Reinigung und Verwendung.
EP0293201A3 (de) Methode zur Impfung gegen Hepatitis-B-Virus
DK43991D0 (da) Allele varianter af plasmodium falciparum merozoitoverfladeantigen
DK123288A (da) Fremgangsmaade til remsning af rekombinant hepatitis b overfladeantigen
DK0419446T3 (da) Kompleks, som er egnet til gennemførelse af en fremgangsmåde til rensning af præ-S-hepatitis-B-virus-overfladeantigen
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
JPS55136234A (en) Hb glycopeptide vaccine
TH3773A (th) วัคซีนป้องกันมาเลเรีย
GB2244273A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.